This clinical trial is focused on studying a skin condition called Prurigo Nodularis. This condition is characterized by itchy, hard bumps on the skin. The study is testing a treatment called Nemolizumab, which is given as a solution for injection. Nemolizumab is also known by its code name, CD14152 or CIM331. The main goal of the study is to assess the long-term safety of Nemolizumab in people with Prurigo Nodularis.
Participants in the study will receive Nemolizumab injections over a period of time. Some participants may receive a placebo instead. The study will monitor the safety of the treatment and how well it works in reducing the symptoms of Prurigo Nodularis. Participants will have regular visits to the study site to receive their injections and to have their health and symptoms checked by the study team.
The study will last for several years, allowing researchers to gather information on the long-term effects of Nemolizumab. Participants will be asked to record their symptoms and any changes they notice using a handheld electronic device provided by the study. This information will help researchers understand how Nemolizumab affects Prurigo Nodularis over time and whether it is a safe and effective treatment option for this condition.
Austria 
Belgium 
Denmark 
France 
Germany 
Hungary 
Italy 
Poland 
Spain 
Sweden 
The Netherlands 
